Result of venetoclax plus/minus azacitidine for R/R MDS
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the updated data from the ongoing…
Related Articles
Switching from C5 inhibition to proximal inhibition in PNH: selecting the right treatment approach
Jens Panse, MD, Aachen University Hospital, Aachen, Germany, discusses the complexities of switching patients with paroxysmal nocturnal hemoglobinuria (PNH) from C5 inhibitors to proximal complement…
COMy 2025 | VJHemOnc
The 11th World Congress on Controversies in Multiple Myeloma (COMy) took place on May 15-18, 2025, in Paris, France. Leading researchers congregated at this meeting…
Welcome! You are invited to join a webinar: Post-EHA 2025 Multiple Myeloma highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading MM experts present summaries on the most significant abstracts from EHA 2025 followed by interactive panel discussions debating current clinical…
Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community
Today’s VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently…
MRD as an early endpoint for accelerated approval in myeloma: current perspectives & future outlooks
Ola Landgren, MD, and Dickran Kazandjian, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, share their excitement around the FDA approval…
Updates in CMML – consensus guidelines, promising therapeutic approaches, the implications of TP53 expression, and more
VJHemOnc is pleased to share a feature article that explores the biology and challenges of VEXAS syndrome.
Serially transplantable, genetically modified PDX models of AML
Binje Vick, PhD, Helmholtz Munich, Munich, Germany, comments on the value of serially transplantable, genetically modified patient-derived xenograft (PDX) models of acute myeloid leukemia (AML).…
Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics
Kai Rejeski, MD, Ludwig-Maximilians University Hospital, Munich, Germany, discusses non-relapse mortality (NRM) in patients receiving CAR T-cells and bispecific antibodies. He highlights that while cytokine…
Welcome! You are invited to join a webinar: Post-EHA 2025 MDS highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading MDS experts present summaries on the most significant abstracts from EHA 2025 followed by interactive panel discussions debating current clinical…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…